To determine the efficacy of forskolin in preventing asthma attacks, we performed a single-blinded clinical study in children and adult out-patients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 h, i.e. three times a day. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%). Values of forced expiratory volume in 1 s and forced expiratory flow, mid-phase, were similar in the two groups during the treatment period. We conclude that forskolin is more effective than sodium cromoglycate in preventing asthma attacks in patients with mild persistent or moderate persistent asthma.
ShuttariMF: Asthma: Diagnosis and management. Am Fam Physician1995; 52: 2225–2235.
2.
HatchGE: Asthma, inhaled oxidants and dietary antioxidants. Am J Clin Nutr1995; 61: 625–630.
3.
FlorenceTM: The role of free radicals in disease. Aust N Z J Ophthalmol1995; 23: 3–7.
4.
BauerKDietersdorferFSertlKKaikBKaikG: Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther1993; 53: 76–83.
5.
GreeneLS: Asthma, oxidants stress, and diet. Nutrition1999; 15: 899–907.
6.
BakerJCTunnicliffeWSDuncansonRAyresJG: Dietary antioxidants and magnesium in type 1 brittle asthma: A case control study. Thorax1999; 54: 115–118.
7.
YousifMHThulesiusO: Forskolin reverses tachyphylaxis to the bronchodilator effects of salbutamol: An in-vitro study on isolated guinea-pig trachea. J Pharm Pharmacol1999; 51: 181–186.
8.
ElenoNGajateEMaciasJGarayRP: Enhancement by reproterol of the ability of disodium cromoglycate to stabilize rat mastocytes. Pulm Pharmacol Ther1999; 12: 55–60.
9.
LindnerEMetzgerH: The action of forskolin on muscle cells is modified by hormones, calcium ions and calcium antagonists. Arzneimittelforschung1983; 33: 1436–1441.
10.
SeamonKBDalyJW: Forskolin: A unique diterpene activator of cyclic AMP-generating systems. Cyclic Nucleotide Res1981; 7: 201–224.
11.
de SouzaNJDohadwallaANRedenJ: Forskolin: A labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev1983; 3: 201–219.
12.
TsukawakiMSuzukiKSuzukiRTakagiKSatakeT: Relaxant effects of forskolin on guinea pig tracheal smooth muscle. Lung1987; 165: 225–237.
13.
PennRBPanettieriRAJrBenovicJL. Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle. Am J Respir Cell Mol Biol1998; 19: 338–348.
14.
TanizawaMWatanabeTKumeHYamakiKMiyamatoKTakagiK: Phosphodiestase IV inhibitors synergistically potentiate relaxation induced by forskolin in guinea-pig trachea. Clin Exp Pharmacol Physiol1998; 25: 114–119.
15.
HidiRTimmermansSLiuESchudtCDentGHolgateST: Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J2000; 15: 342–349.
16.
HallsworthMPTwortCHLeeTHHirstSJ: Beta 2-adrenoreceptor agonists inhibits release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol2001; 132: 729–741.
17.
PangLKnoxAJ: Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J2001; 15: 261–269.
18.
StaplesKJBergmannMTomitaKHouslayMDMcPheeIBarnesPJ: Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol2001; 167: 2074–2080.
19.
YoshidaNSchimizuKKitaichiKHiramatsuKTakeuchiMItoY: Differential effect of phosphodiesterase inhibitor on IL-13, released from peripheral blood mononuclear cells. Clin Exp Immunol2001; 126: 384–389.
AksoyMOMardiniIAYangYBinWZhouSKelsenSG: Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium. J Allergy Clin Immunol2002; 109: 491–497.
22.
DanahayHAthertonHJonesGBridgesRJPollCT: Interleukin-13 induces an hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol2002; 282: 226–236.
23.
FullerRWO'MalleyGBakerAJMacDermotJ: Human alveolar macrophage activation: Inhibition by forskolin but no beta-adrenoreceptor stimulation of phosphodiesterase inhibition. Pulm Pharmacol1988; 1: 101–106.
24.
NiazMASinghRB: Modulation of free radical stress in human red blood cell membrane by forskolin and the prospect for treatment of cardiovascular disease and diabetes. Cell Mol Biol1999; 45: 1203–1207.
25.
National Heart, Lung and Blood Institute: National Asthma Education Program. Highlights of the Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. NIH Pub. 97-405, 1997.
ThorneloeKSNelsonMT. Ion channels in smooth muscle: Regulators of intracellular calcium and contractility. Can J Physiol Pharmacol2005; 83: 215–242.
28.
FitzgeraldDJSpeirWACallahanLA: Office evaluation of pulmonary function. Beyond the numbers. Am Fam Physician1996; 54: 525–534.
29.
DingWQDongMNinovaDHolickyELStegallMDMillerLJ: Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal2003; 15: 27–35.
30.
TascheMJUijenJHBernsenRMde JongsteJCvan der WoudenJC: Inhaled sodium cromoglycate (DSCG) as maintenance therapy in children with asthma: A systematic review. Thorax2000; 55: 913–920.
